Evaluation and Management of Interatrial Septal Aneurysm and Asymmetric Basal Septal Hypertrophy

This patient requires comprehensive evaluation for hypertrophic cardiomyopathy (HCM) with cardiac MRI and assessment for left ventricular outflow tract obstruction (LVOTO), while the interatrial septal aneurysm needs evaluation for associated atrial septal defect and thromboembolic risk.

Asymmetric Basal Septal Hypertrophy - Primary Concern

Immediate Diagnostic Workup

The asymmetric basal septal hypertrophy is the more clinically significant finding and demands systematic evaluation for HCM:

1. Complete 2D Echocardiography with Provocative Maneuvers 1, 2

Measure maximal wall thickness at all LV segments (diagnosis requires ≥15 mm, or ≥13 mm with family history of HCM)
Assess for LVOTO at rest and with Valsalva maneuver or squat-to-stand - critical because resting echo misses up to 50% of obstructive physiology
Evaluate for systolic anterior motion (SAM) of mitral valve
Document mitral regurgitation pattern and severity
Assess LV systolic and diastolic function
Look specifically for LV apical aneurysm (high sudden cardiac death risk)

2. Cardiac MRI - Essential Next Step 3, 2

MRI is superior to echo for detecting focal hypertrophy, particularly at the LV apex, anterolateral wall, and inferoseptum that echo commonly misses 3
Quantify late gadolinium enhancement (LGE) - extensive LGE >15% of LV mass indicates 2-fold increased sudden cardiac death risk 2
Distinguish HCM from mimics (hypertensive heart disease, athlete's heart, infiltrative diseases)
Evaluate for apical aneurysm and papillary muscle abnormalities

3. 12-Lead ECG and 24-48 Hour Holter Monitor 2, 4

Required for initial evaluation and risk stratification
Identify non-sustained ventricular tachycardia (sudden cardiac death risk factor)
Assess for atrial arrhythmias

Critical Differential Diagnosis

Distinguishing HCM from Hypertensive Heart Disease 5, 6:

Features favoring HCM:

Asymmetric hypertrophy with wall thickness >18 mm
Family history of HCM or sudden cardiac death
Marked ECG repolarization abnormalities, Q-waves, or conduction disease
LGE at RV insertion points or localized to thickest segments on MRI
Severe diastolic dysfunction out of proportion to hypertension severity

Features favoring hypertension alone:

Symmetric, mild hypertrophy (<16 mm)
Normal ECG or isolated voltage criteria without repolarization changes
Regression of hypertrophy with 6-12 months of tight BP control (<130 mmHg systolic)

Isolated Basal Septal Hypertrophy (Sigmoid Septum) in Elderly 6:

Common in elderly with hypertension and increased aorto-septal angle
Often associated with mitral annular calcification
May still cause provocable LVOTO requiring stress echo evaluation
Less likely to have familial disease or sarcomeric mutations

Risk Stratification if HCM Confirmed

High-risk features requiring ICD consideration 2:

Massive hypertrophy ≥30 mm
LV apical aneurysm
Extensive LGE >15% of LV mass
Non-sustained ventricular tachycardia on Holter
Family history of sudden cardiac death
Unexplained syncope

Follow-up Protocol

If HCM diagnosed 1, 2:

Serial TTE every 1-2 years in asymptomatic patients
Repeat with any new symptoms
Screen all first-degree relatives with ECG and echo (Table 7 in guidelines)

Interatrial Septal Aneurysm - Secondary Concern

Diagnostic Evaluation

1. Assess for Associated Defects 7, 8, 9

Atrial septal defect (ASD) is the most important association - present in significant proportion of cases
Evaluate for patent foramen ovale (PFO)
Look for evidence of right ventricular volume overload suggesting hemodynamically significant shunt
Measure pulmonary artery pressures

2. Transesophageal Echocardiography (TEE) 8

Consider if transthoracic images inadequate
Better visualization of interatrial septum, thrombus, and shunt
Essential if paradoxical embolism suspected

3. Assess Thromboembolic Risk 8, 9, 10

Document any history of stroke, TIA, or systemic embolization
Evaluate for atrial arrhythmias (associated with ASA)
Look for thrombus within aneurysm

Management Based on Findings

Isolated ASA without complications 8, 11:

Clinical follow-up with periodic echocardiography
No consensus on anticoagulation for isolated ASA without thrombus or shunt
Monitor for development of arrhythmias

ASA with ASD and RV volume overload 7:

Closure indicated (percutaneous device or surgical) to prevent long-term complications
Prevents atrial arrhythmias, heart failure, pulmonary vascular disease

ASA with paradoxical embolism or documented stroke 7:

Closure reasonable even without significant shunt
Consider anticoagulation

ASA with symptomatic arrhythmias 8, 12:

Surgical resection may be considered in highly symptomatic patients
Refer to electrophysiology for arrhythmia management

Critical Pitfalls to Avoid

Do not dismiss basal septal hypertrophy as "normal aging" or "sigmoid septum" without provocative maneuvers and consideration of HCM 5, 6
Do not rely on resting echo alone - up to 50% of LVOTO is missed without Valsalva or exercise provocation 1, 2, 13
Do not assume isolated ASA is benign - always evaluate for ASD, PFO, and thromboembolic history 7, 10
Do not overlook family screening - if HCM confirmed, all first-degree relatives require ECG and echo screening 2, 4
Do not use cardiac CT as first-line - MRI provides superior tissue characterization for HCM evaluation 3, 2

Algorithmic Approach Summary

Step 1: Complete echo with provocative maneuvers → measure wall thickness, assess LVOTO, evaluate for ASA complications

Step 2: If wall thickness ≥13-15 mm or diagnostic uncertainty → Cardiac MRI with LGE

Step 3: ECG + 24-48 hour Holter monitor

Step 4: If HCM confirmed → risk stratification, genetic testing, family screening

Step 5: If ASA with ASD/PFO or embolic history → consider closure

Step 6: Serial follow-up every 1-2 years with repeat imaging

What is the appropriate evaluation and management for a patient whose echocardiogram shows a possible interatrial septal aneurysm and asymmetric basal septal hypertrophy?

Have a follow-up question?